Drug Trial Radar · NCT05738486
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,175
Actual
Start
Feb 28, 2023
Primary completion
May 16, 2024
Study completion May 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Feb 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA. Approximately 375 additional participants will be enrolled in addendum 2. Addendum 3 includes a subset of participants from the main study to receive a single dose. The study will last approximately 91 weeks and include up to 26 visits in the main study.
Conditions
- Alzheimer's Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders
Interventions
DonanemabDrug
Administered IV
PlaceboDrug
Administered IV
DexamethasoneDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)Time frame: 24 Weeks
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
MD First Research - Chandler
Chandler, Arizona
Irvine Clinical Research
Irvine, California
Healthy Brain Clinic
Long Beach, California
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California
JEM Research Institute
Atlantis, Florida
VIN-Julie Schwartzbard
Aventura, Florida
Excel Medical Clinical Trials
Boca Raton, Florida
K2 Medical Research
Clermont, Florida
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Finlay Medical Research
Greenacres City, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
ClinCloud - Maitland
Maitland, Florida
K2 Medical Research
Maitland, Florida
ClinCloud - Viera
Melbourne, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Renstar Medical Research
Ocala, Florida
Charter Research - Winter Park
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Alzheimer's Research and Treatment Center
Stuart, Florida
K2 Medical Research - Tampa
Tampa, Florida
K2 Summit Research
The Villages, Florida
Charter Research - Lady Lake
The Villages, Florida
Alzheimer's Research and Treatment Center
Wellington, Florida
Palm Beach Neurology
West Palm Beach, Florida
Conquest Research
Winter Park, Florida
Columbus Memory Center, LLC
Columbus, Georgia
CenExel iResearch, LLC
Decatur, Georgia
Center for Advanced Research & Education
Gainesville, Georgia
CenExel iResearch, LLC
Savannah, Georgia
MedVadis Research Corporation
Waltham, Massachusetts
Adams Clinical
Watertown, Massachusetts
QUEST Research Institute
Farmington Hills, Michigan
The Cognitive and Research Center of New Jersey
Springfield, New Jersey
Butler Hospital
Providence, Rhode Island
Neurology Clinic, P.C.
Cordova, Tennessee
Gadolin Research
Beaumont, Texas
Kerwin Medical Center
Dallas, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.